Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses

Supernus Pharmaceuticals Inc. (SUPN) reported fourth-quarter 2025 results showing revenue growth alongside operating and net losses.

Total revenues: $211.6 million (+21.5% year over year).

Gross profit: $188.6 million (+27.4% year over year).

Cost of sales: $23.0 million (-11.8% year over year).

Operating loss: $60.2 million (-381.4% year over year).

Net loss attributable to common shareholders: $45.1 million (-394.3% year over year); diluted EPS: -$0.07 (-125.9% year over year).

Balance sheet and cash flow highlights:

Cash from operating activities: $19.9 million (-55.3% year over year).

Purchases of property, plant and equipment: $0.4 million (+100.5% year over year).

Cash and cash equivalents: $128.4 million (+85.3% year over year).

Total liabilities: $390.9 million (+17.6% year over year).

In summary, Supernus (SUPN) delivered strong top-line and gross-profit increases in Q4 2025, but reported an operating and net loss for the quarter and saw a notable decline in operating cash flow compared with the prior year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Supernus Pharmaceuticals Inc. Insider Trading Activity

Supernus Pharmaceuticals Inc. insiders have traded $SUPN stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:

JACK A. KHATTAR (President, CEO) has made 0 purchases and 9 sales selling 188,627 shares for an estimated $9,050,307.
CHARLES W III NEWHALL has made 0 purchases and 2 sales selling 25,000 shares for an estimated $1,269,234.
FRANK MOTTOLA (SVP, Chief Tech. Ops. Officer) has made 0 purchases and 3 sales selling 25,000 shares for an estimated $1,237,500.
BETHANY SENSENIG has made 0 purchases and 2 sales selling 4,475 shares for an estimated $228,264.
PADMANABH P. BHATT (Sr. VP of IP, CSO) sold 710 shares for an estimated $31,552

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Supernus Pharmaceuticals Inc. Hedge Fund Activity

We have seen 167 institutional investors add shares of Supernus Pharmaceuticals Inc. stock to their portfolio, and 180 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MACQUARIE GROUP LTD removed 2,531,537 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $125,817,388
MILLENNIUM MANAGEMENT LLC added 2,293,773 shares (+662.4%) to their portfolio in Q4 2025, for an estimated $114,000,518
WOODLINE PARTNERS LP removed 1,263,811 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,811,406
POLAR CAPITAL HOLDINGS PLC removed 1,002,340 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $47,901,828
CITADEL ADVISORS LLC removed 963,967 shares (-68.0%) from their portfolio in Q4 2025, for an estimated $47,909,159
RUBRIC CAPITAL MANAGEMENT LP removed 595,366 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,589,690
POINT72 ASSET MANAGEMENT, L.P. added 503,316 shares (+28.6%) to their portfolio in Q4 2025, for an estimated $25,014,805

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Supernus Pharmaceuticals Inc. Congressional Stock Trading

Members of Congress have traded $SUPN stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $SUPN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/11 and 1 sale worth up to $15,000 on 10/09.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Supernus Pharmaceuticals Inc. Analyst Ratings

Wall Street analysts have issued reports on $SUPN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 10/29/2025
TD Cowen issued a "Buy" rating on 10/23/2025
Piper Sandler issued a "Overweight" rating on 10/09/2025
Cantor Fitzgerald issued a "Overweight" rating on 09/30/2025

To track analyst ratings and price targets for Supernus Pharmaceuticals Inc., check out Quiver Quantitative's $SUPN forecast page.

Supernus Pharmaceuticals Inc. Price Targets

Multiple analysts have issued price targets for $SUPN recently. We have seen 5 analysts offer price targets for $SUPN in the last 6 months, with a median target of $63.0.

Here are some recent targets:

Annabel Samimy from Stifel set a target price of $55.0 on 12/19/2025
Pavan Patel from B of A Securities set a target price of $65.0 on 10/29/2025
Stacy Ku from TD Cowen set a target price of $60.0 on 10/23/2025
David Amsellem from Piper Sandler set a target price of $65.0 on 10/09/2025
Kristen Kluska from Cantor Fitzgerald set a target price of $63.0 on 09/30/2025